Access Bio (XKRX:950130) Forward Dividend Yield % : 0.00% (As of Jun. 20, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Access Bio Forward Dividend Yield %?

As of today (2024-06-20), the Forward Annual Dividend Yield of Access Bio is 0.00%.

As of today (2024-06-20), the Trailing Annual Dividend Yield of Access Bio is 0.00%.

XKRX:950130's Forward Dividend Yield % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 1.28
* Ranked among companies with meaningful Forward Dividend Yield % only.

Access Bio's Dividends per Share for the three months ended in Mar. 2024 was ₩0.00.

During the past 12 months, Access Bio's average Dividends Per Share Growth Rate was -100.00% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Access Bio's Forward Dividend Yield %

For the Diagnostics & Research subindustry, Access Bio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Access Bio's Forward Dividend Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Access Bio's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Access Bio's Forward Dividend Yield % falls into.

Access Bio Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Access Bio (XKRX:950130) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Access Bio Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Access Bio's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Access Bio (XKRX:950130) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Clyde Road, Suite A, Somerset, NJ, USA, 08873

Website

http://www.accessbio.net

Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

Access Bio (XKRX:950130) Headlines

No Headlines